# US 9,518,126 B2 · Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,518,126 B2
- Document ID: US9518126B2
- Status: Granted
- Kind: B2
- Application number: 12/279,166
- Filed: 2007-11-28
- Published: 2009-11-19
- Granted: 2016-12-13
- Earliest claimed: 2007-11-19
- Assignees: Cellid, Inc.
- Applicants: Chang-Yuil Kang; Hyun-Jeong Ko; Jung-Mi Lee; Yeon-Jeong Kim
- Inventors: Chang-Yuil Kang; Hyun-Jeong Ko; Jung-Mi Lee; Yeon-Jeong Kim
- Web page: https://patentgrep.com/patent/US9518126B2

## CPC

- C07K 16/32: against translation products of oncogenes
- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61K 40/00: Cellular immunotherapy (medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 40/10: characterised by the cell type used
- A61K 40/17: Monocytes; Macrophages
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/34: Antigenic peptides
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2501/999: Small molecules not provided for elsewhere
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.

## Claims

### Claim 1

An immunotherapeutic vaccine comprising immature myeloid cells (IMCs) loaded with a natural killer T cell ligand and a target antigen, the IMCs comprising natural killer T cell ligand loaded on CD1d and a target antigen loaded on major histocompatibility complex (MHC) molecules,
wherein the IMCs are obtained from a tumor-bearing subject;
wherein the IMCs express GR-1 and CD11b simultaneously on their surface;
wherein the natural killer T cell ligand is α-galactosylceramide;
wherein the target antigen is a fragment of a full-length protein derived from a tumor or a pathogen; and
wherein the vaccine activates cytotoxic T cells specific for said target antigen.

### Claim 2 (depends on 1)

The immunotherapeutic vaccine according to claim 1, wherein the pathogenic antigen is a bacterial antigen selected from the group consisting of Bordetella pertussis antigen, tetanus toxoid, diphtheria toxoid, Helicobacter pylori antigen, pneumococcal antigen, tuberculosis antigen, cholera antigen, staphylococcal antigen, shigella antigen, Borrelia sp. antigen, Candida albicans antigen, and Plasmodium antigen.

### Claim 3 (depends on 1)

The immunotherapeutic vaccine according to claim 1, wherein the pathogenic antigen is a viral antigen selected from the group consisting of influenza virus antigen, human papilloma virus (HPV) antigen, vesicular stomatitis virus antigen, cytomegalovirus (CMV) antigen, hepatitis virus antigen, respiratory syncytial virus (RSV) antigen, herpes simplex virus (HSV) antigen, human immunodeficiency virus (HIV) antigen, and combinations thereof.

### Claim 4 (depends on 1)

The immunotherapeutic vaccine according to claim 1, wherein the tumor antigen is selected from the group consisting of Her-2/neu, Proteinase 3, Wilm's Tumor associated gene (WT-1), murinoglobulin, prostatic acid phosphatase (PAP), prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), G250, melanoma antigen (MAGE), B melanoma antigen (BAGE), G melanoma antigen (GAGE), NY-ESO-1 (New York-Esophageal cancer-1), tyrosinase, tyrosinase-related protein-1 (TRP-1), tyrosinase-related protein-2 (TRP-2), gp100 (glycoprotein 100), Melanoma antigen recognized by T cell-1 (MART-1), melanocortin-1 receptor (MC1R), cyclin D-dependent kinase, caspase-8, β-catenin, BCR/ABL, human papillomavirus (HPV) E6/E7, Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2a), Hepatitis C virus (HCV), Human herpes virus, 5T4, carcinoembryonic antigen (CEA), p53, and α-fetoprotein.

### Claim 5 (depends on 1)

The immunotherapeutic vaccine according to claim 1, wherein the target antigen is in the form of a glycoprotein.

### Claim 6 (depends on 1)

A method for treating a cancer or an infectious disease comprising administering to a subject an immunotherapeutic vaccine of claim 1.

### Claim 7

A composition comprising isolated immature myeloid cells (IMCs) loaded with a natural killer T cell ligand and a target antigen, the IMCs comprising a natural killer T cell ligand loaded on CD1d and a target antigen loaded on major histocompatibility complex (MHC) molecules,
wherein the IMCs are obtained from a tumor-bearing subject;
wherein the IMCs express Gr-1 and CD11b simultaneously on their surface;
wherein the natural killer T cell ligand is α-galactosylceramide;
wherein the target antigen is a fragment of a full-length protein derived from a tumor or a pathogen; and
wherein the composition activates cytotoxic T cells specific for said target antigen.